Precision medicine not only promises better treatment, but cost effective healthcare.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Illumina has revealed that it has acquired Edico Genome, with the intention of building on the solid foundation of DRAGEN, to deliver a more streamlines sample for customers.
Medigene has agreed to expand its nearly two-year-old strategic alliance with Bluebird bio, focusing on the research and development of T-cell receptor-modified T-cell immunotherapies (TCR-T) for the treatment of cancer.
The funds will be used to support the next phase in creating Luna DNA’s genomic and medical research platform and enlisting data contributors.
Under the settlement agreement, Oxford Nanopore will refrain from offering its 2D sequencing products in the UK and Germany through the end of 2023.
Researchers are trying to boost the effectiveness of cancer-killing viruses to treat conditions, including brain tumours.
There is concern that the White House is considering imposing further limits on research by Chinese citizens in the United States, saying that “scientific progress depends on openness, transparency, and the free flow of ideas”
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
U.S. regulators approved Novartis’ cell therapy Kymriah for the treatment of patients with a second type of blood cancer.
Thermo Fisher Scientific has signed agreements with Takeda Pharmaceuticals and Daiichi Sanyo that will enable the Japanese firms to leverage Thermo Fisher’s FDA approved Oncomine Dx Target Test for their clinical trials and drug development programs.
The Scripps Translational Science Institute has received over $34 million in renewed funding from the National Institutes of Health’s National Center for Advancing Translational Sciences to advance medical research and clinical care through genomic and digital technologies.
Gilead Sciences will partner with Google Parent Alphabet’s Verily Life Sciences over the next three years, applying Verily’s Immunoscape platform to better understand the immunological basis of three common diseases.